AstraZeneca’s next-generation oral selective estrogen receptor degrader (SERD) camizestrant continues to show promising progress as a targeted therapy for hormone receptor-positive, HER2-negative advanced breast cancer, particularly in patients who develop resistance through ESR1 mutations. As of April 2026, the drug stands on the cusp of potential regulatory approval following compelling data from the pivotal SERENA-6 Phase III trial, which demonstrated its ability to significantly delay disease progression when introduced early upon detection of emerging resistance.
In the SERENA-6 study, researchers used circulating tumor DNA (ctDNA) monitoring to identify ESR1 mutations during first-line endocrine therapy combined with a CDK4/6 inhibitor. Patients who tested positive for the mutation were switched from their aromatase inhibitor to camizestrant while continuing the CDK4/6 inhibitor. This proactive switch reduced the risk of disease progression or death by 56 percent compared to those who remained on standard aromatase inhibitor therapy. Median progression-free survival reached 16.0 months with the camizestrant regimen versus 9.2 months in the control arm, representing a clinically meaningful extension of time without cancer advancement. The results, published in the New England Journal of Medicine and presented at the 2025 ASCO Annual Meeting, marked the first pivotal trial to validate the clinical value of ctDNA-guided intervention before formal disease progression.
Camizestrant works as a complete estrogen receptor antagonist and degrader, effectively blocking and destroying the estrogen receptor protein that fuels many breast cancers. Unlike injectable fulvestrant, camizestrant offers the convenience of a daily oral tablet, potentially improving patient adherence and quality of life. Additional supportive data from the SERENA-3 presurgical study confirmed that the 75 mg once-daily dose—selected for Phase III trials—achieves maximal estrogen receptor reduction and proliferation suppression within days, with good tolerability. Common side effects remained manageable and consistent with the class, including mild gastrointestinal issues during initial treatment.
The innovative design of SERENA-6 addresses a critical unmet need in advanced breast cancer. ESR1 mutations emerge in up to 40 percent of patients on long-term endocrine therapy and drive resistance, limiting the effectiveness of standard treatments. By enabling earlier intervention guided by blood-based biomarker testing, camizestrant offers a precision medicine approach that could reshape first-line management strategies. AstraZeneca has also explored camizestrant in other settings, including combination with various CDK4/6 inhibitors in the SERENA-1 trial, where it demonstrated antitumor activity and acceptable safety across multiple regimens.
Regulatory momentum is building rapidly. The FDA’s Oncologic Drugs Advisory Committee is scheduled to review camizestrant on April 30, 2026, for use in HR-positive, HER2-negative metastatic breast cancer patients with emergent ESR1 mutations during first-line therapy. A PDUFA target action date falls within the first half of 2026, raising hopes for approval that would provide oncologists with a powerful new tool. Breakthrough Therapy Designation has already been granted based on the strength of the SERENA-6 data, underscoring the therapy’s potential to fill a significant gap in care.
For patients, the oral format represents a major advantage over traditional injectable SERDs. Many women with advanced breast cancer value treatments that fit more easily into daily life without frequent clinic visits or injections. Early quality-of-life data from SERENA-6 further support this, showing delayed deterioration in global health status with camizestrant compared to continued aromatase inhibitor use.
As breast cancer research moves toward biomarker-driven and adaptive strategies, camizestrant exemplifies the shift toward personalized oncology. Its ability to target resistance mechanisms before tumors visibly progress could extend the benefits of endocrine-based therapy and delay the need for more toxic chemotherapy options. Ongoing trials continue to evaluate camizestrant in additional combinations and earlier disease settings, broadening its potential impact.
With advisory committee review approaching and strong Phase III evidence in hand, camizestrant is poised to become an important addition to the breast cancer treatment landscape. If approved, it would offer thousands of women a convenient, targeted oral option that directly addresses the challenge of acquired endocrine resistance, bringing new hope for longer progression-free survival and improved daily living.
